SCHEMBL2884909

SCHEMBL2884909

Cc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](c3nc4ccc(-c5ccccc5)cc4[nH]3)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
ALDH1A1 P00352 3/20 0.49
MEN1 O00255 1/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49
KMT2A Q03164 1/20 0.49
HTR2B P41595 2/20 0.49
NPY5R Q15761 1/20 0.47
USP30 Q70CQ3 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
HSD17B10 Q99714 1/20 0.44
HSPD1 P10809 1/20 0.44
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN5 P54829 1/20 0.44
HSPE1 P61604 1/20 0.44
USP2 O75604 1/20 0.44
CYP3A4 P08684 2/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2885187 1.00 MAPT (0.49) MAPTALDH1A1MEN1LMNAHTT
SCHEMBL2885181 0.92 HTR2B (0.49) MAPTALDH1A1MEN1LMNAHTT
SCHEMBL2884904 0.92 HTR2B (0.49) MAPTALDH1A1MEN1LMNAHTT
SCHEMBL2884212 0.86 NPY5R (0.52) MAPTALDH1A1MEN1LMNAHTT
SCHEMBL2879397 0.86 NPY5R (0.52) MAPTALDH1A1MEN1LMNAHTT
SCHEMBL2884131 0.83 NPY5R (0.49) MAPTALDH1A1MEN1LMNAHTT
SCHEMBL2879396 0.77 HTR2B (0.49) KMT2AHTR2BNPY5RUSP30
SCHEMBL2879392 0.77 HTR2B (0.49) KMT2AHTR2BNPY5RUSP30
SCHEMBL2884208 0.77 HTR2B (0.49) KMT2AHTR2BNPY5RUSP30
SCHEMBL2884125 0.75 HTR2B (0.47) HTR2BNPY5RUSP30BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691860-B2 Sulfonamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US claimed
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives MSD K.K. (JP) 2008-07-03 US claimed
EP-1719765-A1 NOVEL SULFONE AMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP claimed
US-7691860-B2 Sulfonamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US disclosed
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives MSD K.K. (JP) 2008-07-03 US disclosed
EP-1719765-A1 NOVEL SULFONE AMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives NPY1R, NPY2R, NPY5R MAPT 1902/4885ALDH1A1 1680/4885MEN1 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.